Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39.

Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

And Denali (Nasdaq: DNLI) is taking a "small" equity stake as well, Tenvie leaders said. What's more, 35-employee Tenvie is subleasing 15,000 square feet from Denali in South San Francisco.

KNOXVILLE, Tenn. (WATE) — The Knox County Highway Department covers nearly 2,000 miles of roadway, excluding state routes like Chapman Highway or the surrounding interstates. The process to get ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Holland America Line, the cruise line with the longest history of exploring Alaska, announced a $70 million capital investment that will expand guest capacity while elevating the line’s Denali ...

MEMPHIS, Tenn. — A Germantown resident who incorporated Halloween decorations into her Christmas display had no idea she would be in trouble with the city. Alexis Luttrell put a skeleton and a ...

SOUTH SAN FRANCISCO - Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI), a biopharmaceutical company currently valued at $3.05 billion and trading below its InvestingPro Fair Value, announced today that ...